The Kable

Share this post

πŸ’Š Amgen bets really, really big on rare diseases; Aspen gets fresh funding to make in Africa

www.daily.thekable.news

πŸ’Š Amgen bets really, really big on rare diseases; Aspen gets fresh funding to make in Africa

A new pathway to treat severe Covid?

Dolly
Dec 13, 2022
1
Share this post

πŸ’Š Amgen bets really, really big on rare diseases; Aspen gets fresh funding to make in Africa

www.daily.thekable.news


Kable #236 has the day’s most interesting stories in pharma, biotech, medtech and healthcare. Summed up to save you time and guaranteed to make you smarter.

Hello, and welcome back to The Kable, where we're discovering that Twitter's quiet decision to end a ban on Covid misinformation is leading, surprisingly, to a spike in anti-vax tweets. Wonder if there's a causal connection here?

Elsewhere, China continues to ease Covid protective measures, and countries everywhere decide (or have already decided) Covid is over. But a state in Mexico is bringing back mask mandates because Covid is back in season over there.

While on the topic of Covid, remember the wild sprouting of digital learning platforms worldwide in the first few locked-down months? Well, a third of those platforms are no longer functional.

Health experts and policy leaders from Africa and around the world are convening in Kigali, Rwanda, for CPHIA 2022, the 2nd International Conference on Public Health in Africa. What excites us at The Kable the most about this conference is that the African Pharmaceutical Technology Foundation is making its formal debut tomorrow at a forum hosted by the AfDB and partners. We're hopeful that the African Pharmaceutical Technology Foundation leads to a massive shift in both drug manufacturing in Africa and also technology ownership.

And finally, in more good news for Africa, the US yesterday said that it is pledging $55 billion in economic, health and security support for Africa over the next three years.

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
Previous
Next
Β© 2023 The Kable
Privacy βˆ™ Terms βˆ™ Collection notice
Start WritingGet the app
SubstackΒ is the home for great writing